Bristol-Myers Squibb’s Yervoy receives FDA nod for use as adjuvant therapy for patients with stage III melanoma
by Staff from Outbreak News Today on (#RZE9)
Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Melanoma, the most aggressive type of skin cancer, is the leading cause of death from skin ["]
